Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296260 | 1.00 | LMNA (0.62) | LMNAKDM4EL3MBTL1POLBPLA2G1B | |
| SCHEMBL1414287 | 1.00 | LMNA (0.62) | LMNAKDM4EL3MBTL1POLBPLA2G1B | |
| SCHEMBL2289990 | 0.88 | LMNA (0.77) | LMNAKDM4EL3MBTL1POLBPLA2G1B | |
| SCHEMBL1849603 | 0.88 | LMNA (0.77) | LMNAKDM4EL3MBTL1POLBPLA2G1B | |
| SCHEMBL7278068 | 0.88 | LMNA (0.77) | LMNAKDM4EL3MBTL1POLBPLA2G1B | |
| SCHEMBL10133058 | 0.85 | LMNA (0.84) | LMNAKDM4EL3MBTL1POLBPLA2G1B | |
| SCHEMBL6458060 | 0.85 | LMNA (0.64) | LMNAKDM4EL3MBTL1POLBPLA2G1B | |
| SCHEMBL2295875 | 0.84 | ADRB2 (0.64) | KDM4EL3MBTL1ADRB3ALDH1A1ADRB2 | |
| SCHEMBL7354606 | 0.84 | MEN1 (0.60) | LMNAKDM4EPOLBPLA2G1BATG4B | |
| SCHEMBL2294551 | 0.84 | ADRB2 (0.64) | KDM4EL3MBTL1ADRB3ALDH1A1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | claimed |
| EP-2809661-B1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2016-04-06 | — | — | EP | disclosed |
| EP-2809661-B1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2016-04-06 | — | — | EP | disclosed |
| CN-104080777-B | Morpholinyl derivatives as MOGAT-2 inhibitors | ELI LILLY AND CO. (US) | 2015-12-09 | — | — | CN | disclosed |
| US-8993568-B2 | Morpholinyl derivatives useful as MOGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993568-B2 | Morpholinyl derivatives useful as MOGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150005305-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-01-01 | — | — | US | disclosed |
| US-20150005305-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2015-01-01 | — | — | US | disclosed |
| CN-104080777-A | Morpholinyl derivatives as MOGAT-2 inhibitors | LILLY CO ELI | 2014-10-01 | — | — | CN | disclosed |
| WO-2013116065-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| CN-102120741-A | Production method of an optically active compound | MITSUBISHI TANABE PHARMA CORP | 2011-07-13 | — | — | CN | disclosed |
| CN-102050820-A | Preparation method of compound with optical activity | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| EP-2221305-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221304-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| CN-101228142-A | Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | LMNA 3268/4885KDM4E 842/4885L3MBTL1 4453/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | LMNA 3268/4885KDM4E 842/4885L3MBTL1 4453/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | LMNA 3268/4885KDM4E 842/4885L3MBTL1 4453/4885 |
| US-20150005305-A1 | NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS | MOGAT2, SOAT2, SOAT1 | LMNA 2462/4885KDM4E 2258/4885L3MBTL1 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.